1. Home
  2. FEIM vs CRDF Comparison

FEIM vs CRDF Comparison

Compare FEIM & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FEIM
  • CRDF
  • Stock Information
  • Founded
  • FEIM 1961
  • CRDF 1999
  • Country
  • FEIM United States
  • CRDF United States
  • Employees
  • FEIM N/A
  • CRDF N/A
  • Industry
  • FEIM Electrical Products
  • CRDF Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • FEIM Industrials
  • CRDF Health Care
  • Exchange
  • FEIM Nasdaq
  • CRDF Nasdaq
  • Market Cap
  • FEIM 173.6M
  • CRDF 185.6M
  • IPO Year
  • FEIM N/A
  • CRDF N/A
  • Fundamental
  • Price
  • FEIM $18.74
  • CRDF $2.87
  • Analyst Decision
  • FEIM
  • CRDF Strong Buy
  • Analyst Count
  • FEIM 0
  • CRDF 4
  • Target Price
  • FEIM N/A
  • CRDF $12.00
  • AVG Volume (30 Days)
  • FEIM 56.1K
  • CRDF 1.5M
  • Earning Date
  • FEIM 03-13-2025
  • CRDF 05-05-2025
  • Dividend Yield
  • FEIM 5.32%
  • CRDF N/A
  • EPS Growth
  • FEIM 604.98
  • CRDF N/A
  • EPS
  • FEIM 2.41
  • CRDF N/A
  • Revenue
  • FEIM $65,400,999.00
  • CRDF $683,000.00
  • Revenue This Year
  • FEIM N/A
  • CRDF N/A
  • Revenue Next Year
  • FEIM N/A
  • CRDF N/A
  • P/E Ratio
  • FEIM $7.61
  • CRDF N/A
  • Revenue Growth
  • FEIM 24.10
  • CRDF 39.96
  • 52 Week Low
  • FEIM $8.62
  • CRDF $2.01
  • 52 Week High
  • FEIM $20.33
  • CRDF $5.64
  • Technical
  • Relative Strength Index (RSI)
  • FEIM 65.94
  • CRDF 43.47
  • Support Level
  • FEIM $17.76
  • CRDF $2.81
  • Resistance Level
  • FEIM $18.65
  • CRDF $3.28
  • Average True Range (ATR)
  • FEIM 0.88
  • CRDF 0.25
  • MACD
  • FEIM 0.23
  • CRDF 0.06
  • Stochastic Oscillator
  • FEIM 94.68
  • CRDF 54.89

About FEIM Frequency Electronics Inc.

Frequency Electronics Inc is engaged in the design, development, and manufacture of high-precision timing, and frequency control products for space, air, sea, and terrestrial applications. The company has FEI-NY and FEI-Zyfer reportable segments. It derives the majority of its revenues from the FEI-NY segment. FEI-NY segment operations consist principally of precision time and frequency control products used in three principal markets namely communication satellites (both commercial and U.S. Government-funded); terrestrial cellular telephone or other ground-based telecommunication stations; and other components and systems for the U.S. military.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

Share on Social Networks: